Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2014

01.07.2014 | Review

Breast cancer and aging: results of the U13 conference breast cancer panel

verfasst von: M. F. Barginear, H. Muss, G. Kimmick, C. Owusu, E. Mrozek, A. Shahrokni, K. Ballman, A. Hurria

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the persisting misalignment between the age distribution of women with breast cancer and the age distribution of participants in clinical trials. The purpose of this report is to state the U13 conference breast cancer panel’s recommendations regarding therapeutic clinical trials that will fill gaps in knowledge regarding the care of older patients with breast cancer. The U13 conference was a collaboration between the Cancer and Aging Research Group and the National Institute on Aging and the National Cancer Institute (NCI). Clinical trials should be developed for frail and vulnerable patients who would not enroll on the standard phase III trials, as well as efforts need to be made to increase enrollment of fit older patients on standard phase III trials. As a result of this conference, panel members are working with the NCI and cooperative groups to address these knowledge gaps. With the aging population and increasing incidence of breast cancer with age, it is essential to study the feasibility, toxicity, and efficacy of cancer therapy in this at-risk population.
Literatur
1.
Zurück zum Zitat Desantis C, Siegel R, Bandi P et al (2011) Breast cancer statistics. CA Cancer J Clin 61:409–418PubMedCrossRef Desantis C, Siegel R, Bandi P et al (2011) Breast cancer statistics. CA Cancer J Clin 61:409–418PubMedCrossRef
2.
Zurück zum Zitat Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241PubMedCrossRef Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241PubMedCrossRef
3.
Zurück zum Zitat Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765PubMedCrossRef Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765PubMedCrossRef
4.
Zurück zum Zitat McDermott AM, Toelle TR, Rowbotham DJ et al (2006) The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 10:127–135PubMedCrossRef McDermott AM, Toelle TR, Rowbotham DJ et al (2006) The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 10:127–135PubMedCrossRef
5.
Zurück zum Zitat McDonald M, Hertz RP, Unger AN et al (2009) Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 64:256–263PubMedCrossRef McDonald M, Hertz RP, Unger AN et al (2009) Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 64:256–263PubMedCrossRef
6.
Zurück zum Zitat Owusu C, Hurria A, Muss H (2012) Adjuvant therapy for older women with early-stage breast cancer: treatment selection in a complex population. Am Soc Clin Oncol Educ Book 32:3–9 Owusu C, Hurria A, Muss H (2012) Adjuvant therapy for older women with early-stage breast cancer: treatment selection in a complex population. Am Soc Clin Oncol Educ Book 32:3–9
7.
Zurück zum Zitat Minino AM, Murphy SL (2012) Death in the United States, 2010. NCHS Data Brief 1–8 Minino AM, Murphy SL (2012) Death in the United States, 2010. NCHS Data Brief 1–8
8.
Zurück zum Zitat Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
9.
Zurück zum Zitat van de Water W, Markopoulos C, van de Velde CJ et al (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307:590–597 van de Water W, Markopoulos C, van de Velde CJ et al (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307:590–597
10.
Zurück zum Zitat Lichtman SM, Wildiers H, Chatelut E et al (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol 25:1832–1843PubMedCrossRef Lichtman SM, Wildiers H, Chatelut E et al (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol 25:1832–1843PubMedCrossRef
11.
Zurück zum Zitat Kemeny MM, Peterson BL, Kornblith AB et al (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268–2275PubMedCrossRef Kemeny MM, Peterson BL, Kornblith AB et al (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268–2275PubMedCrossRef
12.
Zurück zum Zitat Kimmick GG, Muss HB (2001) Systemic therapy for older women with breast cancer. Oncology (Williston Park) 15:280–291; discussion 291–292, 295–296, 299 Kimmick GG, Muss HB (2001) Systemic therapy for older women with breast cancer. Oncology (Williston Park) 15:280–291; discussion 291–292, 295–296, 299
13.
Zurück zum Zitat Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081PubMedCrossRef Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081PubMedCrossRef
14.
Zurück zum Zitat Lichtman SM, Skirvin JA (2000) Pharmacology of antineoplastic agents in older cancer patients. Oncology (Williston Park) 14:1743–1755; discussion 1755, passim Lichtman SM, Skirvin JA (2000) Pharmacology of antineoplastic agents in older cancer patients. Oncology (Williston Park) 14:1743–1755; discussion 1755, passim
15.
Zurück zum Zitat Ramjaun A, Nassif MO, Krotneva S et al (2013) Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol 4:271–281PubMedCrossRef Ramjaun A, Nassif MO, Krotneva S et al (2013) Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol 4:271–281PubMedCrossRef
16.
Zurück zum Zitat Wildes TM, Ruwe AP, Fournier C et al (2013) Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol 4:227–234PubMedCrossRef Wildes TM, Ruwe AP, Fournier C et al (2013) Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol 4:227–234PubMedCrossRef
17.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRef Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRef
18.
Zurück zum Zitat Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465PubMedCentralPubMedCrossRef Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815PubMedCrossRef Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815PubMedCrossRef
20.
Zurück zum Zitat Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217PubMedCrossRef Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217PubMedCrossRef
21.
Zurück zum Zitat Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529PubMedCrossRef Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529PubMedCrossRef
22.
Zurück zum Zitat Bunnell C, Vahdat L, Schwartzberg L et al (2008) Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8:234–241PubMedCrossRef Bunnell C, Vahdat L, Schwartzberg L et al (2008) Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8:234–241PubMedCrossRef
23.
Zurück zum Zitat Cortes J, O’Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923PubMedCrossRef Cortes J, O’Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923PubMedCrossRef
24.
Zurück zum Zitat Blackwell KL MD, Gianni L, et al (2012) Primary results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. 2012 ASCO Annual Meeting. Abstract LBA1. Presented June 3 Blackwell KL MD, Gianni L, et al (2012) Primary results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. 2012 ASCO Annual Meeting. Abstract LBA1. Presented June 3
25.
Zurück zum Zitat Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119PubMedCrossRef Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119PubMedCrossRef
26.
Zurück zum Zitat Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef
27.
Zurück zum Zitat Schwartzberg LS, Franco SX, Florance A et al (2010) Lapatinib plus letrozole as first-line therapy for HER-2 + hormone receptor-positive metastatic breast cancer. Oncologist 15:122–129PubMedCentralPubMedCrossRef Schwartzberg LS, Franco SX, Florance A et al (2010) Lapatinib plus letrozole as first-line therapy for HER-2 + hormone receptor-positive metastatic breast cancer. Oncologist 15:122–129PubMedCentralPubMedCrossRef
Metadaten
Titel
Breast cancer and aging: results of the U13 conference breast cancer panel
verfasst von
M. F. Barginear
H. Muss
G. Kimmick
C. Owusu
E. Mrozek
A. Shahrokni
K. Ballman
A. Hurria
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2994-7

Weitere Artikel der Ausgabe 1/2014

Breast Cancer Research and Treatment 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.